18F-FDG 代谢显像在非小细胞肺癌化疗后疾病稳定期患者疗效评估中的价值_《中国呼吸与危重监护杂志》

作者：

程腾 ¹ , 孙丽华 ¹ , 王峰 ² , 谷伟 ¹ , 谭焰 ¹

1 南京医科大学附属南京医院/南京市第一医院呼吸科( 江苏南京210006);;
2 南京医科大学附属南京医院/ 南京市第一医院核医学科( 江苏南京210006) 通信作者: 孙丽华, E-mail: nfhsun@ sina. com;

关键词：

非小细胞肺癌脱氧葡萄糖代谢显像疾病稳定期疗效评估

DOI：

DOI: 10 . 7507 /1671 -6205 . 20130111

视频：

导出 下载 收藏 扫码 引用

摘要 全文 图表 视频 参考文献 施引文献 补充材料

目的探讨18 F标记的脱氧葡萄糖( 18F-FDG) 代谢显像在非小细胞肺癌疾病稳定期患者化疗疗效评估中的价值。
方法回顾性分析28 例非小细胞肺癌稳定期患者化疗前后18 F-FDG 代谢显像的靶/ 非靶摄取值变化率( ΔT/N) , 并随访3 ～12 个月得到无进展生存期( PFS) , 分析ΔT/N与PFS 之间的相关性。根据ΔT/N不同将患者分为代谢减少组、代谢无减少组, 比较两组患者PFS 之间差异。
结果非小细胞肺癌稳定期患者化疗后ΔT/N与PFS 之间呈正相关( r = 0. 668, P lt; 0. 01) , 代谢减少组PFS 较代谢无明显减少组PFS 显著延长[ ( 8. 0 ±2. 5) 个月比( 5. 3 ±1. 2) 个月, P lt;0. 05] 。
结论非小细胞肺癌稳定期患者化疗后ΔT/N值的不同可预示PFS的差异。

引用本文： 程腾 ,孙丽华,王峰,谷伟,谭焰. 18F-FDG 代谢显像在非小细胞肺癌化疗后疾病稳定期患者疗效评估中的价值. 中国呼吸与危重监护杂志, 2013, 12(5): 461-464. doi: DOI: 10 . 7507 /1671 -6205 . 20130111 复制

1.	Steinert HC. PET and PET-CT of lung cancer. Methods Mol Biol,2011, 727: 33-51.
2.	赖灿, 杨建伟, 张江灵, 等. 探讨18 F-FDG SPECT-CT 在胃癌疗效评价中的价值. 肿瘤防治研究, 2010 , 37: 679-682.
3.	Festuccia C, Gravina GL, Millimaggi D, et al. Uncoupling of the epidermal growth factor receptor from downstream signal transduction molecules guides the acquired resistance to gefitinib inprostate cancer cells. Oncol Rep, 2007 , 18: 503-511.
4.	Ceresoli GL, Gregorc V, Cordio S, et al. Phase II study of weekly paclitaxel as second-line therapy in patients with advanced nonsmall cell lung cancer. Lung Cancer, 2004, 44: 231-239.
5.	Behzadi A, Ung Y, Lowe V, et al. The role of positron emission tomography in the management of non-small cell lung cancer. Can J Surg, 2009, 52: 235-242.
6.	Kong FM, Frey KA, Quint LE, et al. A pilot study of [ 18 F] fluoro deoxy glucose positron emission tomography scans during and after radiation-based therapy in patients with non-small-cell lung cancer.J Clin Oncol, 2007, 25 : 3116-3123.
7.	Lee DH, Kim S, Lee H, et al. Early prediction of response to firstline therapy using integrated 18 F-FDG PET/ CT for patients with advanced metastatic non-small cell lung cancer. J Tborac Oncol,.
8.	Mudd SR, Voorbach MJ, Reuter DR, et al. FDG-PET as a pharmacodynamic biomarker for early assessment of treatment response to linifanib ( ABT-869 ) in a non-small cell lung cancerxenograft model. Cancer Chemother Pharmacol, 2012, 69: 1669 -1672.
9.	Takahashi R, Hirata H, Tachibana I, et al. Early [ 18 F]fluorodeoxyglucose positron emission tomography at two days of gefitinib treatment predicts clinical outcome in patients with adenocarcinoma of the lung. Clin Cancer Res, 2012, 18 : 220-228 .
10.	Nahmias C, Hannal WT, Wahl LM, et al. Time course of early response to chemotherapy in non-small cell lung cancer patients with 18 F-FDG PET/ CT. J Nucl Med, 2007, 48: 744-751 .
11.	Richard L, Heather J, Yvette K, et al. From RECIST to PERCIST: evolving considerations for PET response criteria in solidtumors. J Nucl Med, 2009 , 50: 122S-150S.
12.	Pottgen C, Levegrum S, Theegarten D, et al. Value of 18 F -fluoro-2-deoxy-D-glucose-positron emission tomography/ computed tomography in non-small-cell lung cancer for prediction of pathologic response and times to relapse after neoadjuvant chemoradiotherapy.Clin Cancer Res, 2006, 12: 97-106.
13.	, 4: 816-21.

1. Steinert HC. PET and PET-CT of lung cancer. Methods Mol Biol,2011, 727: 33-51.
2. 赖灿, 杨建伟, 张江灵, 等. 探讨18 F-FDG SPECT-CT 在胃癌疗效评价中的价值. 肿瘤防治研究, 2010 , 37: 679-682.
3. Festuccia C, Gravina GL, Millimaggi D, et al. Uncoupling of the epidermal growth factor receptor from downstream signal transduction molecules guides the acquired resistance to gefitinib inprostate cancer cells. Oncol Rep, 2007 , 18: 503-511.
4. Ceresoli GL, Gregorc V, Cordio S, et al. Phase II study of weekly paclitaxel as second-line therapy in patients with advanced nonsmall cell lung cancer. Lung Cancer, 2004, 44: 231-239.
5. Behzadi A, Ung Y, Lowe V, et al. The role of positron emission tomography in the management of non-small cell lung cancer. Can J Surg, 2009, 52: 235-242.
6. Kong FM, Frey KA, Quint LE, et al. A pilot study of [ 18 F] fluoro deoxy glucose positron emission tomography scans during and after radiation-based therapy in patients with non-small-cell lung cancer.J Clin Oncol, 2007, 25 : 3116-3123.
7. Lee DH, Kim S, Lee H, et al. Early prediction of response to firstline therapy using integrated 18 F-FDG PET/ CT for patients with advanced metastatic non-small cell lung cancer. J Tborac Oncol,.
8. Mudd SR, Voorbach MJ, Reuter DR, et al. FDG-PET as a pharmacodynamic biomarker for early assessment of treatment response to linifanib ( ABT-869 ) in a non-small cell lung cancerxenograft model. Cancer Chemother Pharmacol, 2012, 69: 1669 -1672.
9. Takahashi R, Hirata H, Tachibana I, et al. Early [ 18 F]fluorodeoxyglucose positron emission tomography at two days of gefitinib treatment predicts clinical outcome in patients with adenocarcinoma of the lung. Clin Cancer Res, 2012, 18 : 220-228 .
10. Nahmias C, Hannal WT, Wahl LM, et al. Time course of early response to chemotherapy in non-small cell lung cancer patients with 18 F-FDG PET/ CT. J Nucl Med, 2007, 48: 744-751 .
11. Richard L, Heather J, Yvette K, et al. From RECIST to PERCIST: evolving considerations for PET response criteria in solidtumors. J Nucl Med, 2009 , 50: 122S-150S.
12. Pottgen C, Levegrum S, Theegarten D, et al. Value of 18 F -fluoro-2-deoxy-D-glucose-positron emission tomography/ computed tomography in non-small-cell lung cancer for prediction of pathologic response and times to relapse after neoadjuvant chemoradiotherapy.Clin Cancer Res, 2006, 12: 97-106.
13. , 4: 816-21.

《中国呼吸与危重监护杂志》

18F-FDG 代谢显像在非小细胞肺癌化疗后疾病稳定期患者疗效评估中的价值

摘要 全文 图表 视频 参考文献 施引文献 补充材料

上一篇

下一篇

Format

Content

《中国呼吸与危重监护杂志》

18F-FDG 代谢显像在非小细胞肺癌化疗后疾病稳定期患者疗效评估中的价值

摘要 全文 图表 视频 参考文献 施引文献 补充材料

上一篇

下一篇

Format

Content

摘要全文图表视频参考文献施引文献补充材料